ARDT Ardent Health (ARDT) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-general medical & surgical hospitals, nec · CIK 0001756655
C-suite buying · 1Form 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
88
13F, latest reported quarter
What the filings say about ARDT
Insiders, 180 days
+$186.4K net bought
2 buyers
Planned sales (Form 144), 90 days
$1.6M
4 notices
Ardent Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Ardent Health, Inc. insiders bought a net $186.4K of stock across 4 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 31.7% of the 35,564 shares held after it.
- 1 other insider bought within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeMichiei Robert bought about $98.3K of ARDT on Jun 5, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 88 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.0% of the 329,183 shares held after it.
- 1 other insider bought within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer LUMSDAINE ALFRED bought about $88.1K of ARDT on Jun 5, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 88 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 24.8% of the 40,275 shares held after it.
- No other insider bought within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Webb Robert Thomas bought about $164.9K of ARDT on Nov 8, 2024, the largest insider purchase at the company on our record; 88 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.0% of the 30,275 shares held after it.
- No other insider bought within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Webb Robert Thomas bought about $174.7K of ARDT on Nov 8, 2024, the largest insider purchase at the company on our record; 88 funds added in the latest 13F quarter.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$186.4K over 180 days
more than 84% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
88 funds bought in last quarter
below 68% of Healthcare Services
Revenue
+6.0% year over year
below 63% of Healthcare Services
Margin
2.1% net margin
more than 58% of Healthcare Services
Buybacks
$13.0M repurchased, FY to 2026-06-30
below 77% of Healthcare Services
Short interest
21.3% of the float short (float per yahoo 2026-10-26) · 10.7 days to cover · settled 2026-09-30
below 51% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ARDT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.1%12M
Insider buyForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ARDT: institutional holders (13F)
13F holdings, latest reported quarter
77,246,499 sh
$760.1M
9,342,501 sh
$91.9M
2,176,348 sh
$21.4M
2,110,599 sh
$20.8M
1,580,423 sh
$15.5M
Congress trades in ARDT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ARDT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Bonick Martin
Filed 2026-08-27
$398.0K
Bonick Martin
Filed 2026-08-25
$401.4K
Bonick Martin
Filed 2026-08-20
$377.4K
Bonick Martin
Filed 2026-08-18
$393.5K
ARDT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust Small Cap Value AlphaDEX Fund
$1.3M position · as of 2026-07-31
0.7%
VY Columbia Small Cap Value and Inflection Portfolio
$362.5K position · as of 2026-06-30
0.5%
Columbia Small Cap Value and Inflection Fund
$4.2M position · as of 2026-05-31
0.5%
Columbia Small Cap Value Discovery Fund
$11.0M position · as of 2026-07-31
0.4%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$1.8M position · as of 2026-06-30
0.4%
iShares US Small Cap Value Factor ETF
$768.0K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Marty Bonick
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.1M
-$3.2M
$2.0M
-45%
+5%
2024
$6.9M
$18.7M
$2.5M
+6%
-6%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $186.4K bought by insiders over 180 days, 88 funds added last quarter, $1.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ARDT financials
Revenue growth
+6.0%
XBRL, annual
Net margin
2.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ARDT
| FY Dec 2025 | $6.3B |
| FY Dec 2024 | $6.0B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.6B |
| Sep 2025 | $1.6B |
| Jun 2025 | $1.6B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.6B |
| Sep 2024 | $1.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+1.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ARDT
| FY Dec 2025 | +2.1% |
| FY Dec 2024 | +3.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +1.0% |
| Mar 2026 | +2.5% |
| Dec 2025 | +2.8% |
| Sep 2025 | -1.5% |
| Jun 2025 | +4.4% |
| Mar 2025 | +2.8% |
| Dec 2024 | +7.1% |
| Sep 2024 | +1.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ARDT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.82x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ARDT
| FY Dec 2025 | 0.85x |
| FY Dec 2024 | 0.97x |
| FY Dec 2023 | 1.77x |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.82x |
| Mar 2026 | 0.83x |
| Dec 2025 | 0.85x |
| Sep 2025 | 0.89x |
| Jun 2025 | 0.88x |
| Mar 2025 | 0.94x |
| Dec 2024 | 0.97x |
| Sep 2024 | 1.09x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.47x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ARDT
| FY Dec 2025 | 0.43x |
| FY Dec 2024 | 0.29x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.47x |
| Mar 2026 | 0.39x |
| Dec 2025 | 0.43x |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.28x |
| Dec 2024 | 0.29x |
| Sep 2024 | 0.24x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ARDT
| FY Dec 2025 | +11.2% |
| FY Dec 2024 | +23.3% |
| FY Dec 2023 | +6.3% |
| FY Dec 2022 | n/a |
| Jun 2026 | +6.0% |
| Mar 2026 | +10.7% |
| Dec 2025 | +11.2% |
| Sep 2025 | +18.3% |
| Jun 2025 | +25.6% |
| Mar 2025 | +19.7% |
| Dec 2024 | +23.3% |
| Sep 2024 | +8.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ARDT
| FY Dec 2025 | +2.7% |
| FY Dec 2024 | +4.3% |
| FY Dec 2023 | +1.1% |
| FY Dec 2022 | n/a |
| Jun 2026 | +1.5% |
| Mar 2026 | +2.6% |
| Dec 2025 | +2.7% |
| Sep 2025 | +4.1% |
| Jun 2025 | +5.3% |
| Mar 2025 | +4.6% |
| Dec 2024 | +4.3% |
| Sep 2024 | +1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ARDT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ARDT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.51x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ARDT
| FY Dec 2025 | 9.20x |
| FY Dec 2024 | 10.81x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 17.89x |
| Mar 2026 | 9.01x |
| Dec 2025 | 9.20x |
| Sep 2025 | 8.95x |
| Jun 2025 | 7.42x |
| Mar 2025 | 8.28x |
| Dec 2024 | 10.81x |
| Sep 2024 | 25.89x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.0B
market value at close 2026-10-27 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ARDT
| FY Dec 2025 | $1.7B |
| FY Dec 2024 | $3.0B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $1.8B |
| Mar 2026 | $1.7B |
| Dec 2025 | $1.7B |
| Sep 2025 | $2.4B |
| Jun 2025 | $2.5B |
| Mar 2025 | $2.6B |
| Dec 2024 | $3.0B |
| Sep 2024 | $3.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield ARDT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -70%, PEG needs growth
PEG, trailing ARDT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.04x |
| Mar 2025 | 0.05x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.3B | $6.0B | $5.4B | $5.1B |
| Net income | $135.8M | $210.3M | $53.9M | $188.9M |
| EPS (diluted) | 0.96 | 1.58 | 0.43 | 1.50 |
| Operating cash flow | $470.5M | $315.0M | $221.7M | -$38.4M |
| Cash | $709.6M | $556.8M | $437.6M | n/a |
| Long-term debt | $1.1B | $1.1B | $1.2B | n/a |
| Dividends paid | n/a | $0 | $0 | $174.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
ARDT Stock Sonar score 6/7 axes
Find similar shapesCompareARDT ranks highest on insider conviction (86th percentile) and profitability (59th), and lowest on institutional and government (32nd), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ARDT filings, in plain words
Are Ardent Health insiders buying or selling ARDT?
In the 180 days to 2026-10-28, Ardent Health insiders were net buyers, a net $186.4K across purchases and sales reported on Form 4, by 2 buyers.
Are there planned insider sales of ARDT?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.6M of stock; the latest, by Bonick Martin, was filed 2026-08-27.
Read the full summary
In the 180 days to 2026-10-28, Ardent Health insiders were net buyers of ARDT, a net $186.4K across purchases and sales reported on Form 4 by 2 buyers. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
